相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Managing advanced prostate cancer in the Asia Pacific region: Real-world application of Advanced Prostate Cancer Consensus Conference 2019 statements
Edmund Chiong et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2022)
Impact of New Systemic Therapies in Overall Survival in Non-Metastatic Castration Resistant Prostate Cancer: Systematic Review and Meta-Analysis
Alejo Rodriguez-Vida et al.
CLINICAL GENITOURINARY CANCER (2022)
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis
Lin Wang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)
Apalutamide and Overall Survival in Prostate Cancer
Matthew R. Smith et al.
EUROPEAN UROLOGY (2021)
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
Philip Cornford et al.
EUROPEAN UROLOGY (2021)
Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis
Mathieu Roumiguie et al.
FUTURE ONCOLOGY (2021)
Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC).
Tomasz M. Beer et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Molecular determinants associated with long-term response to apalutamide (APA) in nonmetastatic castration-resistant prostate cancer (nmCRPC).
Felix Y. Feng et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial.
Matthew Raymond Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and physician's perception according to patient comorbidities
Fernando Maluf et al.
INTERNATIONAL BRAZ J UROL (2021)
Novel Androgen Receptor Inhibitors in Non-Metastatic, Castration-Resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis
Yelin Mulati et al.
FRONTIERS IN ONCOLOGY (2021)
Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
Susan Halabi et al.
JOURNAL OF UROLOGY (2021)
Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease
Matthew R. Smith et al.
CLINICAL CANCER RESEARCH (2021)
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial
Matthew R. Smith et al.
EUROPEAN JOURNAL OF CANCER (2021)
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials
Jaleh Fallah et al.
LANCET ONCOLOGY (2021)
Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer
Felix Y. Feng et al.
JAMA ONCOLOGY (2021)
A Systematic Review and Meta-Analysis of Randomized Controlled Trials With Novel Hormonal Therapies for Non-Metastatic Castration-Resistant Prostate Cancer: An Update From Mature Overall Survival Data
Martina Maggi et al.
FRONTIERS IN ONCOLOGY (2021)
Understanding Treatment Strategies and Preferences in Nonmetastatic Castration-Resistant Prostate Cancer From the Japanese Physician Perspective
Kazuhiro Suzuki et al.
JCO GLOBAL ONCOLOGY (2021)
Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials
G. Roviello et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
Systemic Management for Nonmetastatic Castration-resistant Prostate Cancer A Systematic Review and Network Meta-Analysis
Zefu Liu et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2020)
A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer
Amanda E. Hird et al.
CLINICAL GENITOURINARY CANCER (2020)
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
Silke Gillessena et al.
EUROPEAN UROLOGY (2020)
An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer
Michael Brave et al.
CLINICAL CANCER RESEARCH (2020)
Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy
Anuj Shah et al.
JOURNAL OF MEDICAL ECONOMICS (2020)
Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer
Pravien Rajaram et al.
MOLECULES (2020)
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Cora N. Sternberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
C. Parker et al.
ANNALS OF ONCOLOGY (2020)
Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment
Sandy Srinivas et al.
CANCER MEDICINE (2020)
Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study
Hiroji Uemura et al.
PROSTATE INTERNATIONAL (2020)
Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis
Jatinder Kumar et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2020)
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Sandy Srinivas et al.
BMC UROLOGY (2020)
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Keiichiro Mori et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study
Hiroji Uemura et al.
BMC UROLOGY (2020)
A case of toxic epidermal necrolysis associated with apalutamide administration
Nobuko Sagawa et al.
JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY (2020)
Managing Nonmetastatic Castration-resistant Prostate Cancer
Joaquin Mateo et al.
EUROPEAN UROLOGY (2019)
A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III)
E. David Crawford et al.
JOURNAL OF UROLOGY (2019)
Higher blood brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography.
Christian Zurth et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial
Bertrand Tombal et al.
LANCET ONCOLOGY (2019)
Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study
Amy Downing et al.
LANCET ONCOLOGY (2019)
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio
Kyo Chul Koo et al.
WORLD JOURNAL OF UROLOGY (2019)
Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017
Marniza Saad et al.
BJU INTERNATIONAL (2019)
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes
Vincenzo Di Nunno et al.
CLINICAL GENITOURINARY CANCER (2019)
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer
Wolfgang P. Fendler et al.
CLINICAL CANCER RESEARCH (2019)
Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies
Christian Zurth et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2019)
Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial
Neal Shore et al.
TARGETED ONCOLOGY (2019)
Blood-brain barrier penetration of [14C]darolutamide compared with [14C]enzalutamide in rats using whole body autoradiography.
Christian Zurth et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Metastasis-free Survival - A New End Point in Prostate Cancer Trials
Julia A. Beaver et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Examining relationships between age at diagnosis and health-related quality of life outcomes in prostate cancer survivors
Christine J. Kurian et al.
BMC PUBLIC HEALTH (2018)
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial
Fred Saad et al.
LANCET ONCOLOGY (2018)
Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naive and CYP17 Inhibitor-naive Patients: Follow-up from the ARADES and ARAFOR Trials
Neal D. Shore et al.
EUROPEAN UROLOGY FOCUS (2018)
NCCN Asia Consensus Statement prostate cancer
Shiro Hinotsu et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2018)
Network meta-analysis: an introduction for clinicians
Benjamin Rouse et al.
INTERNAL AND EMERGENCY MEDICINE (2017)
Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naive Prostate Cancer: Results from Extended Follow-up of the ARADES Trial
Karim Fizazi et al.
EUROPEAN UROLOGY FOCUS (2017)
Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study
Christophe Massard et al.
EUROPEAN UROLOGY (2016)
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
Karim Fizazi et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
Anu-Maarit Moilanen et al.
SCIENTIFIC REPORTS (2015)
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
Karim Fizazi et al.
LANCET ONCOLOGY (2014)
Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis
X. Yuan et al.
ONCOGENE (2014)
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Nicola J. Clegg et al.
CANCER RESEARCH (2012)
Disease and Host Characteristics as Predictors of Time to First Bone Metastasis and Death in Men With Progressive Castration-Resistant Nonmetastatic Prostate Cancer
Matthew R. Smith et al.
CANCER (2011)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer
MR Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prostate cancer and health-related quality of life: A review of the literature
DT Eton et al.
PSYCHO-ONCOLOGY (2002)
分享论文
